Systemic-onset juvenile idiopathic arthritis
MONDO:0019434Systemic-onset juvenile idiopathic arthritis is marked by the severity of the extra-articular manifestations (fever, cutaneous eruptions) and by an equal sex ratio.
Also known as: SoJIA, Still disease, sJIA, systemic polyarthritis, systemic-onset JIA, Still's disease (formerly), systemic juvenile idiopathic arthritis, systemic onset juvenile idiopathic arthritis
59 clinical trials for this condition and its sub-types, 25 tagged with Systemic-onset juvenile idiopathic arthritis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New antibody tested to tame childhood arthritis and cut steroid use
Disease control Recruiting nowResearchers are testing an experimental drug called GenaKumab in children and teens with active systemic juvenile idiopathic arthritis, a condition that causes joint inflammation and recurring fevers. The trial enrolls about 290 participants aged 2 to under 18 who have had sympto…
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill could ease severe childhood arthritis
Disease control Recruiting nowThis study tests a new oral medication, upadacitinib, in children aged 1 to 17 with active systemic juvenile idiopathic arthritis (sJIA), a rare and serious form of arthritis that can affect the whole body. About 90 participants will receive either upadacitinib or the standard in…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for Still's disease: experimental drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called MAS825 for people with Still's disease, a rare inflammatory condition causing fever, rash, and joint pain. About 20 children and adults with active disease will receive the drug to see if it safely controls symptoms. The goal is to improve d…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for kids with arthritis: Long-Term drug study launches
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of the drug filgotinib in children and adolescents aged 8 to 17 with juvenile idiopathic arthritis. Participants must have already completed a previous filgotinib study and shown improvement. The goal is to see if the d…
Phase 3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New study tracks ilaris use in rare inflammatory diseases across europe
Disease control Recruiting nowThis study looks at how patients with Familial Mediterranean Fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis and adult-onset Still's disease) use the drug canakinumab (Ilaris) over the long term. Researchers will track 160 patients across Europe …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for kids with rare arthritis: drug dose study underway
Disease control Recruiting nowThis study is for children and teens aged 1 to 17 with systemic juvenile idiopathic arthritis (sJIA), a condition that causes joint swelling and fever. Researchers are testing different doses of the drug sarilumab to find the best amount that works and is safe. The study involves…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Real-world check: does ilaris work safely for rare fever diseases?
Disease control Recruiting nowThis study watches children and adults who are already taking or about to start Ilaris for hereditary periodic fever syndromes or systemic juvenile idiopathic arthritis. Researchers will track side effects and how well the drug controls symptoms over 16 weeks. No new medicine is …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Milder transplant method aims to help young patients with rare blood diseases
Disease control Recruiting nowThis study is testing a less intense chemotherapy and radiation regimen before a stem cell transplant for children and young adults up to age 55 with non-cancerous blood disorders like immune deficiencies, anemias, and metabolic diseases. The goal is to see if this gentler prepar…
Phase 2 • Sponsor: Paul Szabolcs • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Massive study aims to unlock secrets of rare inflammatory diseases
Knowledge-focused Recruiting nowThis study is for people with certain autoinflammatory diseases (like NOMID, DIRA, CANDLE, SAVI, and others) and their healthy relatives. Researchers want to learn more about what causes these diseases and how they affect the body over time. Participants will have medical tests a…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists launch deep dive into mysterious inflammatory diseases
Knowledge-focused Recruiting nowThis study aims to understand the causes and progression of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD) by observing up to 2,000 participants over time. Researchers will collect medical history, blood samples, and genetic data to identify …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
5,000 patients to help unlock secrets of inflammatory heart disease
Knowledge-focused Recruiting nowThis study aims to learn how well heart scans (MRI, ultrasound, PET) can detect and predict outcomes in people with suspected or known inflammatory heart diseases. Researchers will follow 5,000 adults for one year to see how often heart involvement is confirmed and how it affects…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Major study launches to unravel mysteries of rare still disease in kids and adults
Knowledge-focused Recruiting nowThis study will follow 500 adults and children with Still disease, a rare inflammatory condition causing fever, joint pain, and rash. Researchers aim to compare how the disease affects different age groups, identify early markers, and improve care. No new treatments are being tes…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC